
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics is a global medical company with a Buy rating and a price target of $110 due to expected earnings and strong partnerships with CSL Plasma. The company's focus on its fast-growing MedSurg segment, along with recent supply agreements with CSL, is expected to drive growth and profitability. However, competition and external factors such as tariffs and cybersecurity pose potential risks. With a strong presence in the Apheresis and MedSurg segments, Haemonetics is well positioned for continued success and achieving top EBIT margins in the MedTech industry.
Bears say
Haemonetics is facing headwinds in the blood center and hospital segments due to competition and pricing pressures. The company's revised guidance for FY2027 only calls for modest growth, and profitability may be impacted by ongoing investments and higher operating expenses. The current market conditions and company outlook suggest a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares